Barclays raised the firm’s price target on Privia Health (PRVA) to $22 from $21 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview for the health care facilities and managed care group. The firm continues to think Medicare is the most stable, Medicaid the most uncertain, and the Affordable Care Act exchanges are inflecting positively from both a fundamental and policy perspective.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Strategic Acquisition Boosts Privia Health’s Growth Potential with Evolent Health’s ACO Business
- Privia Health Group: Hold Rating Amid Growth Prospects and Integration Risks Post-Evolent Health Acquisition
- Privia Health Acquires ACO Business for $100 Million
- Privia Health to acquire ACO business from Evolent Health for $100M in cash
- Evolent Health to sell Evolent Care Partners to Privia Health for up to $113M